Medexus Pharmaceuticals Inc. (TSX:MDP)

Medexus Pharmaceuticals Cash Flow Statement

Financials in millions USD. Fiscal year is April - March.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
Net Income	2.25	-0.21	1.22	-2.88	-28.26
Depreciation & Amortization	7.18	5.81	6.08	6.14	5.98
Other Amortization	-	-	-	0	0
Asset Writedown & Restructuring Costs	2.8	0.89	-	1.75	-
Stock-Based Compensation	0.41	0.47	1.22	1.88	1.27
Other Operating Activities	5.55	9.42	5.3	-12.81	25.88
Change in Accounts Receivable	10.54	-1.68	-8.24	4.43	-3.51
Change in Inventory	-4.6	-6.75	-1.99	-6.66	-0.01
Change in Accounts Payable	-1.99	8.58	4.75	3.61	4.63
Change in Other Net Operating Assets	1.9	2.19	-9.79	3.36	-0.93
Operating Cash Flow	24.03	18.71	-1.44	-1.18	5.04
Operating Cash Flow Growth	28.43%	-	-	-	-
Capital Expenditures	-0.18	-0.05	-0.06	-0.1	-0.12
Cash Acquisitions	-3.28	-3.21	-1.36	-0.48	-0.95
Sale (Purchase) of Intangibles	-2.54	-0.22	-0.3	-7.62	-10.64
Investing Cash Flow	-6	-3.48	-1.72	-8.2	-11.71
Long-Term Debt Issued	-	17.58	35.46	3.89	0.35
Long-Term Debt Repaid	-14.24	-43.99	-24.72	-0.16	-0.37
Net Debt Issued (Repaid)	-14.24	-26.4	10.73	3.73	-0.02
Issuance of Common Stock	19.3	7.61	-	-	22.64
Other Financing Activities	-4.27	-4.25	-4.33	-3.07	-3.93
Financing Cash Flow	0.8	-23.05	6.41	0.66	18.68
Foreign Exchange Rate Adjustments	-0.11	-0	-0.19	0.03	1.45
Net Cash Flow	18.72	-7.81	3.05	-8.69	13.47
Free Cash Flow	23.85	18.66	-1.51	-1.28	4.92
Free Cash Flow Growth	27.79%	-	-	-	-
Free Cash Flow Margin	22.02%	16.51%	-1.39%	-1.67%	6.18%
Free Cash Flow Per Share	0.90	0.84	-0.07	-0.06	0.32
Cash Interest Paid	4.27	4.25	4.33	3.07	3.64
Cash Income Tax Paid	0.22	1.42	0.91	0.68	0.87
Levered Free Cash Flow	28.32	8.47	-8.98	-10.18	-8.96
Unlevered Free Cash Flow	33.44	16.83	-0.48	-2.54	-2.82
Change in Net Working Capital	-20.49	-2.36	13.08	-4.47	-0.03

Source: S&P Global Market Intelligence. Standard template. Financial Sources.